Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06882746 · ClinicalTrials.gov registry record · Phase 1
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
A Phase 1 study of Pancreatic Ductal Adenocarcinoma and Colorectal Carcinoma, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 135
- Enrollment target
- 3
- Study locations
NCT06882746 is a Phase 1 study of Pancreatic Ductal Adenocarcinoma and Colorectal Carcinoma that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 135 participants, below the 599-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06882746, a Phase 1 study of Pancreatic Ductal Adenocarcinoma and Colorectal Carcinoma, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 135 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread. People can take part in this study if their previous treatment was not successful, or no other treatment exists. The study aims to find the highest dose for the study medicine called BI 765049 that people with advanced cancer can tolerate. Another purpose is to find the most suitable dose and best way of administration of BI 765049 for further clinical development. BI 765049 may help the immune system fight cancer. Participants receive BI 765049 at least once every 3 weeks. Participants may continue to get BI 765049 treatment as long as they benefit from treatment and can tolerate it. Participants in this study also get additional medication before and after treatment with BI 765049 for better tolerability. If participants take this medication at home, they have daily phone visits. Participants regularly visit the study site. The study visits include several overnight stays at the hospital. At the visits, study doctors check participants' health, take necessary laboratory tests, and note any unwanted effects. Unwanted effects are any health problems that the doctors think were caused by the study medicine or treatment. To find the highest dose of BI 765049 that participants can tolerate, researchers look at the number of participants with certain severe health problems. These are severe health problems that happen within the time from when a person first receives the intended target dose, until one week after they receive it for the second time.
Conditions Studied
Interventions
- DRUG BI 765049
Study Locations (3)
California
- Valkyrie Clinical Trials - Los Angeles
Georgia
- Winship Cancer Institute - Atlanta
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2025-03-28 |
| Est. Completion | 2027-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06882746
The ClinicalTrials.gov registry entry for NCT06882746 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 599-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (77% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which BI 765049 is the first listed.
NCT06882746 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Georgia, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06882746 about?
NCT06882746 is a clinical study titled "A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas". This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread. People can take part in this study if their previous treatment was not successful, or no other treatment exists. The study aims to find the hi...
What is the current status of trial NCT06882746?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 135 participants. The study started on 2025-03-28. Estimated completion is 2027-05-12.
What conditions does trial NCT06882746 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma, Colorectal Carcinoma, Gastric Carcinoma.
What interventions are being tested in trial NCT06882746?
The interventions under investigation include: BI 765049 (DRUG).
Who is sponsoring clinical trial NCT06882746?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06882746 being conducted?
This trial has 3 study locations across California, Georgia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.